炎症负荷对突破性缺血性卒中结局的影响:ASPERA-R研究
ASPERA-R登记研究中671例突破性缺血性卒中患者,基于入院中性粒细胞/淋巴细胞比值等构建复合炎症负荷指数。高炎症负荷与90天缺血事件、全因死亡、中重度出血及24小时出血转化风险增加相关。常规炎症生物标志物组合或有助于识别残余血管高危患者。
要点
- 高炎症负荷与突破性卒中后90天缺血事件风险增加相关(HR 1.53)。
- 高炎症负荷与全因死亡(HR 1.70)和中重度出血(HR 2.92)风险增加相关。
- 高炎症负荷与24小时出血转化风险增加相关(OR 2.18)。
核心结论
- 在突破性缺血性卒中患者中,高炎症负荷与90天复发性缺血事件、全因死亡、出血转化及中重度出血风险增加独立相关。
- 由常规可获得的炎症生物标志物构建的复合指数可能有助于识别残余血管风险较高的患者。
研究设计与样本
- 多中心回顾性队列研究,数据来自ASPERA-R登记。
- 纳入671例来自14个中心的突破性缺血性卒中患者,具有完整生物标志物数据;中位年龄80.1岁(IQR 73.5–85.5),女性占52.3%。
- 炎症负荷基于入院中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值、系统性免疫炎症指数和C反应蛋白,经对数转换和Z分数标准化后合成复合指数。
- 按炎症负荷三分位分组:高炎症负荷组(上三分位)223例(33.2%),低炎症负荷组(下两个三分位)448例(66.8%)。
- 采用逆概率处理加权调整中心、人口学特征、血管危险因素与合并症、抗凝治疗、竞争性卒中病因、基线NIHSS评分、卒中前mRS及采血时间。
主要发现
- 高炎症负荷组90天缺血事件风险增加(HR 1.53,95% CI 1.02–2.30)。
- 高炎症负荷组全因死亡风险增加(HR 1.70,95% CI 1.17–2.47)。
- 高炎症负荷组中重度出血风险增加(HR 2.92,95% CI 1.04–8.17)。
- 高炎症负荷组24小时出血转化风险增加(OR 2.18,95% CI 1.43–3.33)。
临床怎么用
- 对于接受口服抗凝治疗仍发生缺血性卒中的房颤患者,入院时可计算基于NLR、PLR、SII和CRP的复合炎症负荷指数以辅助风险分层。
- 高炎症负荷患者可能需更密切监测复发缺血事件、出血转化及出血风险。
局限性
- 回顾性队列研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stroke, Ahead of Print. BACKGROUND:Patients with atrial fibrillation who experience ischemic stroke despite oral anticoagulation (breakthrough stroke) remain at high risk of recurrent vascular events and death. Although inflammation has been associated with thromboembolic risk, its prognostic role in breakthrough stroke remains unclear. We investigated whether a composite inflammatory burden index was associated with adverse outcomes after breakthrough ischemic stroke.METHODS:We conducted a multicenter retrospective cohort study of consecutive patients with breakthrough ischemic stroke from the ASPERA-R registry. Inflammatory burden was assessed using admission neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune–inflammation index, and C-reactive protein. Biomarkers were log-transformed, standardized usingZscores, and combined into a composite inflammatory burden index. Patients were classified as having high (upper tertile) or lower inflammatory burden (lower 2 tertiles). Outcomes included new 90-day ischemic events (recurrent ischemic stroke, transient ischemic attack, or systemic embolism), 24-hour hemorrhagic transformation, and 90-day moderate-to-severe bleeding, intracranial hemorrhage, and mortality. Inverse probability of treatment weighting accounted for center, demographics, vascular risk factors and comorbidities, anticoagulation, competing stroke causes, baseline National Institutes of Health Stroke Scale, prestroke modified Rankin Scale, and time to blood collection.RESULTS:Among 1649 patients enrolled in ASPERA-R, 671 patients from 14 centers had complete biomarker data (median age, 80.1 years [interquartile range, 73.5–85.5]; 52.3% female). Of these, 223 (33.2%) had high inflammatory burden, and 448 (66.8%) had lower inflammatory burden. After weighting, high inflammatory burden was associated with increased risks of ischemic events at 90 days (hazard ratio, 1.53 [95% CI, 1.02–2.30]), all-cause mortality (hazard ratio, 1.70 [95% CI, 1.17–2.47]), moderate-to-severe bleeding (hazard ratio, 2.92 [95% CI, 1.04–8.17]), and hemorrhagic transformation at 24 hours (odds ratio, 2.18 [95% CI, 1.43–3.33]).CONCLUSIONS:In breakthrough ischemic stroke, high inflammatory burden was associated with increased risks of recurrent ischemic events, mortality, hemorrhagic transformation, and major bleeding. A composite of routinely available inflammatory biomarkers may help identify patients with higher residual vascular risk.
引用
- Stroke:Impact of Inflammatory Burden on Outcomes After Breakthrough Ischemic Stroke: Insights From the ASPERA-R Study
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。